Laura Deming’s Longevity Fund seeds a company developing new therapies for chronic age-related diseases. Longevity took part in Rubedo Life Sciences’ $12 million round, which also included Khosla Ventures, Refactor Capital and Shanda.
Based in Sunnyvale, Calif., Rubedo is developing therapies targeting senescent cells that drive age-related diseases. The company will use the funding to advance its lead candidates in respiratory diseases with significant unmet medical need, such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. It will then look to advance preclinical candidates in oncology, neurodegenerative conditions, skeletal muscle disorders and other age-related diseases. In a statement, Laura said her firm was “impressed by the science, exceptional team and the rate of progress” at Rubedo.
Longevity also recently backed Elevian, Inc., which is seeking to treat and prevent multi age-related diseases. Earlier this year, a firm portfolio company, Metacrine, Inc., went public. Longevity’s investments also include Epirium Bio, Inc., which is developing treatments for progressive neuromuscular disorders.